OBJECTIVE: To describe the phenotype of patients with C9FTD/ALS (C9ORF72) hexanucleotide repeat expansion. METHODS: A total of 648 patients with frontotemporal dementia (FTD)-related clinical diagnoses and Alzheimer disease (AD) dementia were tested for C9ORF72 expansion and 31 carried expanded repeats (C9+). Clinical and neuroimaging data were compared between C9+ (15 behavioral variant FTD [bvFTD], 11 FTD-motor neuron disease [MND], 5 amyotrophic lateral sclerosis [ALS]) and sporadic noncarriers (48 bvFTD, 19 FTD-MND, 6 ALS). RESULTS: All C9+ patients displayed clinical syndromes of bvFTD, ALS, or FTD-MND. At first evaluation, C9+ bvFTD patients had more delusions and greater impairment of working memory, but milder eating dysregulation compared to bvFTD noncarriers. C9+FTD-MND patients had a trend for longer survival and had an earlier age at onset than FTD-MND noncarriers. Voxel-based morphometry demonstrated more thalamic atrophy in FTD and FTD-MND carriers than in noncarriers. CONCLUSIONS: Patients with the C9ORF72 hexanucleotide repeat expansion develop bvFTD, ALS, or FTD-MND with similar clinical and imaging features to sporadic cases. Other FTD spectrum diagnoses and AD dementia appear rare or absent among C9+ individuals. Longer survival in C9+ FTD-MND suggests slower disease progression and thalamic atrophy represents a novel and unexpected feature.
OBJECTIVE: To describe the phenotype of patients with C9FTD/ALS (C9ORF72) hexanucleotide repeat expansion. METHODS: A total of 648 patients with frontotemporal dementia (FTD)-related clinical diagnoses and Alzheimer disease (AD) dementia were tested for C9ORF72 expansion and 31 carried expanded repeats (C9+). Clinical and neuroimaging data were compared between C9+ (15 behavioral variant FTD [bvFTD], 11 FTD-motor neuron disease [MND], 5 amyotrophic lateral sclerosis [ALS]) and sporadic noncarriers (48 bvFTD, 19 FTD-MND, 6 ALS). RESULTS: All C9+ patients displayed clinical syndromes of bvFTD, ALS, or FTD-MND. At first evaluation, C9+ bvFTD patients had more delusions and greater impairment of working memory, but milder eating dysregulation compared to bvFTD noncarriers. C9+FTD-MNDpatients had a trend for longer survival and had an earlier age at onset than FTD-MND noncarriers. Voxel-based morphometry demonstrated more thalamic atrophy in FTD and FTD-MND carriers than in noncarriers. CONCLUSIONS:Patients with the C9ORF72hexanucleotide repeat expansion develop bvFTD, ALS, or FTD-MND with similar clinical and imaging features to sporadic cases. Other FTD spectrum diagnoses and AD dementia appear rare or absent among C9+ individuals. Longer survival in C9+ FTD-MND suggests slower disease progression and thalamic atrophy represents a novel and unexpected feature.
Authors: Stephen M Wilson; Simona M Brambati; Roland G Henry; Daniel A Handwerker; Federica Agosta; Bruce L Miller; David P Wilkins; Jennifer M Ogar; Maria Luisa Gorno-Tempini Journal: Brain Date: 2008-11-20 Impact factor: 13.501
Authors: H J Rosen; M L Gorno-Tempini; W P Goldman; R J Perry; N Schuff; M Weiner; R Feiwell; J H Kramer; B L Miller Journal: Neurology Date: 2002-01-22 Impact factor: 9.910
Authors: Adam L Boxer; Ian R Mackenzie; Bradley F Boeve; Matthew Baker; William W Seeley; Richard Crook; Howard Feldman; Ging-Yuek R Hsiung; Nicola Rutherford; Victor Laluz; Jennifer Whitwell; Dean Foti; Eric McDade; Jennifer Molano; Anna Karydas; Aleksandra Wojtas; Jill Goldman; Jacob Mirsky; Pheth Sengdy; Stephen Dearmond; Bruce L Miller; Rosa Rademakers Journal: J Neurol Neurosurg Psychiatry Date: 2010-06-20 Impact factor: 10.154
Authors: Sid E O'Bryant; Laura H Lacritz; James Hall; Stephen C Waring; Wenyaw Chan; Zeina G Khodr; Paul J Massman; Valerie Hobson; C Munro Cullum Journal: Arch Neurol Date: 2010-06
Authors: Elisa Majounie; Yevgeniya Abramzon; Alan E Renton; Rodney Perry; Susan S Bassett; Olga Pletnikova; Juan C Troncoso; John Hardy; Andrew B Singleton; Bryan J Traynor Journal: N Engl J Med Date: 2012-01-04 Impact factor: 91.245
Authors: Yu Zhang; Norbert Schuff; Christopher Ching; Duygu Tosun; Wang Zhan; Marzieh Nezamzadeh; Howard J Rosen; Joel H Kramer; Maria Luisa Gorno-Tempini; Bruce L Miller; Michael W Weiner Journal: Int J Alzheimers Dis Date: 2011-06-27
Authors: Nikolas R Block; Sharon J Sha; Anna M Karydas; Jamie C Fong; Mary G De May; Bruce L Miller; Howard J Rosen Journal: Am J Geriatr Psychiatry Date: 2015-06-21 Impact factor: 4.105
Authors: Georges Naasan; Gil D Rabinovici; Pia Ghosh; Jonathan D Elofson; Bruce L Miller; Giovanni Coppola; Anna Karydas; Jamie Fong; David Perry; Suzee E Lee; Jennifer S Yokoyama; William W Seeley; Joel H Kramer; Michael W Weiner; Norbert Schuff; William J Jagust; Lea T Grinberg; Mochtar Pribadi; Zhongan Yang; Renee Sears; Eric Klein; Kevin Wojta; Howard J Rosen Journal: Neurocase Date: 2015-06-04 Impact factor: 0.881
Authors: Stacey Li Hi Shing; Mary Clare McKenna; We Fong Siah; Rangariroyashe H Chipika; Orla Hardiman; Peter Bede Journal: Brain Imaging Behav Date: 2021-01-05 Impact factor: 3.978